153 related articles for article (PubMed ID: 24949692)
1. [Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].
Li P; Kang X; Chen K
Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):496-500. PubMed ID: 24949692
[No Abstract] [Full Text] [Related]
2. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
3. [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer].
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Shen-Tu JZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):540-6. PubMed ID: 23086647
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
5. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
6. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
7. [Current translational research status of ERCC1 expression of
non-small cell lung cancer].
Cui S; Jiang L
Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):428-32. PubMed ID: 24854562
[No Abstract] [Full Text] [Related]
8. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 and non-small-cell lung cancer.
Zhou SF
N Engl J Med; 2007 Jun; 356(24):2540; author reply 2540-1. PubMed ID: 17575590
[No Abstract] [Full Text] [Related]
10. ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Zhang H; Li J; Zhang Y; Sun M; Zhao P; Zhang G; Jin C; Sun L; He M; Wang B; Zhang X
Genet Mol Res; 2014 Dec; 13(4):10215-22. PubMed ID: 25501233
[TBL] [Abstract][Full Text] [Related]
11. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
Bepler G; Kusmartseva I; Sharma S; Gautam A; Cantor A; Sharma A; Simon G
J Clin Oncol; 2006 Oct; 24(29):4731-7. PubMed ID: 16966686
[TBL] [Abstract][Full Text] [Related]
12. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Zheng Z; Chen T; Li X; Haura E; Sharma A; Bepler G
N Engl J Med; 2007 Feb; 356(8):800-8. PubMed ID: 17314339
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 and non-small-cell lung cancer.
Panasci L; Cohen V
N Engl J Med; 2007 Jun; 356(24):2540; author reply 2540-1. PubMed ID: 17575589
[No Abstract] [Full Text] [Related]
14. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
15. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
[TBL] [Abstract][Full Text] [Related]
16. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
[TBL] [Abstract][Full Text] [Related]
17. DNA repair and survival in lung cancer--the two faces of Janus.
Gazdar AF
N Engl J Med; 2007 Feb; 356(8):771-3. PubMed ID: 17314336
[No Abstract] [Full Text] [Related]
18. ERCC1 and RRM1 Expression in nonsmall cell lung cancer--the good, the bad and the unknown.
Singh N; Aggarwal AN
J Thorac Oncol; 2009 Aug; 4(8):1042-3. PubMed ID: 19633482
[No Abstract] [Full Text] [Related]
19. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
